Related Experiment Video

Updated: Aug 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

PHARMAC and the statin debacle

Chris Ellis1, Harvey White

  • 1Greenlane Cardiovascular Service, Auckland City Hospital, Auckland. chrise@adhb.govt.nz

The New Zealand Medical Journal
|June 30, 2006
PubMed

Insights

Statins effectively reduce cardiovascular events by lowering LDL cholesterol. However, PHARMAC

Area of Science:

  • Cardiovascular Medicine
  • Pharmacoeconomics

Background:

  • Statins are proven lipid-modifying drugs that significantly reduce cardiovascular events like heart attacks and strokes.
  • Clinical trials demonstrate a 1% reduction in major coronary heart disease events for every 1% decrease in LDL cholesterol.
  • Optimal management guidelines emphasize low LDL cholesterol levels (1.6 mmol/L) for high-risk patients.

Purpose of the Study:

  • To review PHARMAC's actions regarding statin availability in New Zealand.
  • To analyze how PHARMAC's methods impact the timely delivery of modern medicines.

Main Methods:

  • Review of historical data and actions by PHARMAC concerning statin procurement and availability.
  • Analysis of the impact of PHARMAC's drug management strategies on patient access to statins.

Main Results:

  • PHARMAC's actions have impeded the optimal management of New Zealand patients requiring statins.
  • The focus on low drug prices by PHARMAC has hindered timely access to essential cardiovascular medications.

Conclusions:

  • PHARMAC's approach prioritizes cost reduction over timely patient access to effective statin therapy.
  • A review of PHARMAC's methods highlights systemic issues in drug delivery to New Zealand patients.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...